Around twenty months is the normal median survival time for those who
have been diagnosed with a brain tumor by medical professionals. Brain tumors are
responsible for around 1.6% of all known cases of tumors, and they are responsible for
2.5% of the total death rates. Brain tumors present a number of problems that need to
be recognized and overcome before they can be properly treated. There are a number of
barriers that are present in this scenario. These barriers include the blood-brain tumor
barrier (BBTB), the blood-brain barrier (BBB), the presence of efflux pumps, the
diversity of tumor cells, antibiotic resistance, the tumor microenvironment (TME), and
cancer stem cells (CSCs), which cause immune evasion, as well as the infiltration and
invasion of tumor cells. Treatment of brain tumors with receptor-mediated drug
delivery systems that make use of targeted nanoparticles (NPs) is one of the most
advantageous approaches. This is due to the fact that there is a strong desire to make
use of the potential that is offered by these systems. Particularly in the field of medical
administration, the emphasis is placed on the utilization of research in order to target
particular receptors. A damaged blood-brain barrier is associated with increased levels
of expression of low-density lipoprotein receptors, which are commonly referred to as
LDLR. These receptors are found in both healthy and diseased brains. The influence of
LDLR-mediated therapy in the treatment of brain tumors was the key topic of
discussion that we focused on in this chapter.
Keywords: Brain tumor, Low-density lipoprotein receptor, Low-density lipoproteins, Nanoparticles.
